Evidence map›Paper›PMID 34741188›Full record

ArticleClinical and experimental medicine2022

Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination.

Davide Firinu, Andrea Perra, Marcello Campagna, Roberto Littera, Giuseppe Fenu, Federico Meloni, Selene Cipri, Francesca Sedda, Maria Conti, Michela Miglianti and 9 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Davide FirinuDepartment of Medical Sciences and Public Health, Policlinico Universitario - AOU di Cagliari, University of Cagliari, Azienda Ospedaliero Universitaria, SS 554-Bivio Sestu, 09042, Monserrato, Cagliari, CA, Italy. davide.firinu@unica.it.ORCID http://orcid.org/0000-0002-5768-391X
Andrea PerraDepartment of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
Marcello CampagnaDepartment of Medical Sciences and Public Health, Policlinico Universitario - AOU di Cagliari, University of Cagliari, Azienda Ospedaliero Universitaria, SS 554-Bivio Sestu, 09042, Monserrato, Cagliari, CA, Italy.
Roberto LitteraAssociazione per l'Avanzamento della Ricerca per i Trapianti O.d.V., Non Profit Organisation, Cagliari, Italy.
Giuseppe FenuDepartment of Neuroscience, A.O. Brotzu, Cagliari, Italy.
Federico MeloniDepartment of Medical Sciences and Public Health, Policlinico Universitario - AOU di Cagliari, University of Cagliari, Azienda Ospedaliero Universitaria, SS 554-Bivio Sestu, 09042, Monserrato, Cagliari, CA, Italy.
Selene CipriMedical Genetics, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Francesca SeddaDepartment of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
Maria ContiDepartment of Medical Sciences and Public Health, Policlinico Universitario - AOU di Cagliari, University of Cagliari, Azienda Ospedaliero Universitaria, SS 554-Bivio Sestu, 09042, Monserrato, Cagliari, CA, Italy.
Michela MigliantiDepartment of Medical Sciences and Public Health, Policlinico Universitario - AOU di Cagliari, University of Cagliari, Azienda Ospedaliero Universitaria, SS 554-Bivio Sestu, 09042, Monserrato, Cagliari, CA, Italy.
Giulia CostanzoDepartment of Medical Sciences and Public Health, Policlinico Universitario - AOU di Cagliari, University of Cagliari, Azienda Ospedaliero Universitaria, SS 554-Bivio Sestu, 09042, Monserrato, Cagliari, CA, Italy.
Marta SecciDepartment of Medical Sciences and Public Health, Policlinico Universitario - AOU di Cagliari, University of Cagliari, Azienda Ospedaliero Universitaria, SS 554-Bivio Sestu, 09042, Monserrato, Cagliari, CA, Italy.
Gianmario UsaiDepartment of Medical Sciences and Public Health, Policlinico Universitario - AOU di Cagliari, University of Cagliari, Azienda Ospedaliero Universitaria, SS 554-Bivio Sestu, 09042, Monserrato, Cagliari, CA, Italy.
Mauro Giovanni CartaDepartment of Medical Sciences and Public Health, Policlinico Universitario - AOU di Cagliari, University of Cagliari, Azienda Ospedaliero Universitaria, SS 554-Bivio Sestu, 09042, Monserrato, Cagliari, CA, Italy.
Riccardo CappaiLaboratory Clinical Chemical Analysis and Microbiology, University Hospital of Cagliari, Cagliari, Italy.
Germano OrrùDepartment of Medical Sciences and Public Health, Policlinico Universitario - AOU di Cagliari, University of Cagliari, Azienda Ospedaliero Universitaria, SS 554-Bivio Sestu, 09042, Monserrato, Cagliari, CA, Italy.
Stefano Del GiaccoDepartment of Medical Sciences and Public Health, Policlinico Universitario - AOU di Cagliari, University of Cagliari, Azienda Ospedaliero Universitaria, SS 554-Bivio Sestu, 09042, Monserrato, Cagliari, CA, Italy.
Ferdinando CogheLaboratory Clinical Chemical Analysis and Microbiology, University Hospital of Cagliari, Cagliari, Italy.
Luchino ChessaDepartment of Medical Sciences and Public Health, Policlinico Universitario - AOU di Cagliari, University of Cagliari, Azienda Ospedaliero Universitaria, SS 554-Bivio Sestu, 09042, Monserrato, Cagliari, CA, Italy.
University of Cagliari · ITAzienda Ospedaliera G. Brotzu · ITAzienda Ospedaliero-Universitaria Cagliari · IT

Funding

fondazione di sardegna 2020.2197
6 · The paper itself

Abstract

SARS-CoV-2 vaccination with mRNA product BNT162b2 elicited high immunogenicity in healthy subjects in trials. This study aims to better understand the factors that influence the humoral immune response to vaccination against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMIDs). We enrolled patients and healthy healthcare workers control group (HCW) that underwent mRNA BNT162b2 vaccination and measured the serum IgG anti-S-RBD response at booster dose (T1), one month after booster dose (T2) and up to 5 months (T3). Demographic, disease-specific and vaccination data were recorded. Vaccination response of 551 participants naïve to SARS-CoV-2 infection were included in HCW and 102 in the IMID group, analyzing separately those on anti-CD20. At T2 all naïve HCW developed anti-S-RBD-IgG, while 94% of IMID responded (p < 0.001). IMID patients had a significantly different level of IgG than HCW at both T1 (p = 0.031), T2 (p < 0.001), while there was no significant difference at T3. There were no statistically significant differences according to the IMID type or to ongoing treatment with immunosuppressants, corticosteroids or biological drugs other than anti-CD20. The proportion and magnitude of response was significantly lower in IMID treated with anti-CD20 drugs. There was a correlation with age at T1 and at T2 but not at T3, stronger in patients than in HCW. Immune response close after BNT162b2 vaccination is reduced in patients with IMID, but there is no significant difference at 5 months. The measured reduction is related to age and the disease itself rather than treatments, with the exception of anti-CD20 drugs.

Indexed as

Antibody FormationCOVID-19BNT162 VaccineCOVID-19 VaccinesHumansImmunoglobulin GInfantRNA, MessengerSARS-CoV-2VaccinationBNT162 VaccineCOVID-19 VaccinesImmunoglobulin GRNA, MessengerAutoimmune diseaseBNT162b2Covid-19IMIDImmunogenicityVaccination

Identifiers

PMID34741188
PMCPMC8570239
OpenAlexW3189087670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.